简介：ObjectToinvestigatetheclinicalsignificanceofallogeneichematopoieticstemcelltransplantation(allo-HSCT)followingfludarabine(Flu)-basednomnyeloablativeconditioningregimen.Methods7patientswitholderageororgandysfunctionreceivedeitheroftwoFlu-basednonmyeloablativeconditioningprotocolsfollowedbyinfusionofgranulocytecolony-stimulatingfactor(G-CSF)mobilizedallogeneicperipheralblooclstemcells(PBSC).Cy-elosporincombiningmethotrexatewasusedasgraftvshostdisease(GVHD)prophylaxis.ResultsMinimalalloHSCTassociatedtoxicitywasfoundapartfrommucositis.Theallogeneicdonorengraftmentswereverifiedinallthepatients.Sixofseveneasessurvivedmorethan5months.AcuteGVHDoccurredinthreeofsevenpatientsincludingacaseofgrade1IGVHD.ConclusionTherapidengrafunentofallo-PBSCandgraftvsleukemia(GVL)effectscanbeobtainedbyFlu-basednomnyeloablativeconditioningregimen.Thismanagementissuitableforthepatientswhoaretoooldorhaveorgandysfunction.

简介：瞄准：为tadalafil的20mg的二dosing政体检验偏爱，在需求或三次上每星期，在在Italy.Methods与可勃起的机能障碍(编辑)影响的人：安排了使用，包含转线路andopen标签学习在意大利集中的94泌尿学对在需求政体评估上(肯定)一多集中，。与编辑影响至少3个月的18岁以上的病人每星期在需求或三次上被注册并且使随机化5-6星期到tadalafil治疗的20mg。在1星期的冲刷以后，病人们被穿过在上到为5-6星期的交替的政体。一个治疗偏爱问题被用来决定比较喜欢的治疗政体。可勃起的功能(IIEF)和性相遇侧面(9月)的国际索引问询表被用作功效措施。结果：1058个人(吝啬的年龄54.8years)的一个总数，被使随机化到治疗。总的来说，59.1%病人比较喜欢每星期dosing比较喜欢三次的按需的政体and41.9%。两政体有效、很好容忍。尽管IIEF可勃起的功能(IIEF-EF)的统计上更高的改进领域分数和SEP问询表与on-demandtreatment政体相比每星期在三次被报导，这差别在临床的significance.Conclusion数字地最小、缺乏：Tadalafil有效、很好容忍是否每星期在需求或三次上使用。病人们应该被给选择根据个人需要和偏爱选择最好的治疗政体。

简介：Purpose:Wntpathwayscontrolkeybiologicalprocessesthatpotentiallyimpactontumorprogressionandpatientsurvival.Thepresentstudyanalyzedthepolymorphismoflipoprotein-relatedreceptor5(LRP5)(genewithkeyfunctionsinWntsignaling)anditsimpactontheresponsetochemotherapyandsurvivalofpatientswithadvancedgastriccancer(AGC).Methods:Atotalof107consecutivepatientswithAGCtreatedwithfirst-linechemotherapyofEOFregimenwereenrolledinthepresentretrospectivestudy.Theassociationbetweensinglenucleotidepolymorphism(SNP)ofrs3736228inLRP5andtheclinicaloutcomesofthepatientswasstudied.Results:TheCCgenotypeofrs3736228wassignificantlycorrelatedwithahigherdiseasecontrolratewhencomparedtotheCTandTTgenotypes(89.3%and61.8%,respectively,P<0.001).Aunivariatesurvivalanalysisalsoshowedthattheprogressionfreesurvival(PFS)andoverallsurvival(OS)forthepatientswiththeTCandTTgenotypesofrs3736228wereworsethanforthepatientswiththeCCgenotype(PFS:3.3and6.7months,respectively,HR=0.454,P<0.001;OS:8.1monthsand18.8months,respectively,HR=3.056,P<0.001).AmultivariateCoxmodelincorporatesrs3736228andclinicalfeatures,alsoidentifiedrs3736228wassignificantlyassociatedwiththePFSandOS.Conclusions:OurresultsfirstlyhighlighttheimportanceofLRP5geneofWntpathwayinthetreatmentofAGCandidentifypolymorphismofrs3736228asindependentpredictorofdiseasecontrolrate,PFSandOSinAGCpatientstreatedwithfirst-linechemotherapyofEOFregimenintheChineseHanpopulation.

简介：Objective:Toanalyzelong-termoutcomeinsixtyleukemiapatientsreceivedallogeneichematopoieticstemcelltransplantation(allo-HSCT)followingbusulfanandcyclophosphamide(BU-CY2)between1994and2000.Methods:BU-CY2wasusedastheconditioningregimenandallo-HSCTwasperformedforallpatients.Allthepatientswerefollowed-upuntilAugust2001ordeath.Theleukemia-freesurvival,relapseandtransplant-relatedmortalitywerediscussed.Results:All60patientshadsustainedengraftment.AcuteGVHDoccurredin22outof60patients(36.7%),andtheincidenceofacuteGVHDwas48%inthepatientswithCML,30%inAMLand26.7%inALL.38patientsarestillaliveincontinuousremissionwithamedianfollow-upof30months(range12-84)and22patientshavedied.ThemaincausesofdeathwereacuteGVHDin3patients,CMV-IPin7patientsandrelapsein11patients,theremainingonediedofpulmonaryinfection.Among11patientswhodiedofrelapse,8patientswithALLrelapsedintheearlystageposttransplant(8/15,53.3%),relapsewasobservedintheremaining3patientswithAML,andhowever,norelapsewasobservedinCML.Theprobabilityofdisease-freesurvivalat3yearsforCML.AMLandALLpatientswas80%,70%and26.7%,respectively.Conclusion:ThisresultssuggeststhatBU-CY2isaneffectiveconditioningregimeninpatientswithAMLandCML,resultinginalowrelapserateandhighlong-termsurvivalrate,butnotaseffectiveinpatientswithALL,withahigherincidenceofrelapseandtherefore,notrecommendedforALLpatients.

简介：无

简介：Objective:Apreviousstudydemonstratedthatnon-anthracycline-containingdocetaxelpluscyclophosphamide(TC)regimenwasinferiortodocetaxel,anthracyclineandcyclophosphamide(TAC)inneoadjuvanttreatmentoftriple-negativebreastcancer(TNBC)andhumanepidermalgrowthfactorreceptor-2-(HER2)-positivebreastcancerinashort-termfollow-up.Herein,long-termfollow-upsurvivaloutcomeshavebeeninvestigated.Methods:TNBCorHER2-positivepatientswererandomizedtoreceive6cyclesofTCorTACneoadjuvanttreatment.Theprimaryendpointwaspathologicalcompleteremission(pCR).Secondaryendpointsincludedclinicalresponserate,event-freesurvival(EFS),andoverallsurvival(OS).Results:Acohortof96patientsconsistedof45inTCand51inTACarm.Withamedianfollow-upperiodof53(range,8–76)months,thepatientsachievingpCRpostneoadjuvantchemotherapyexhibitedsuperiorEFSandOSthanpatientswithoutpCR(P<0.05).TACtreatmentresultedinconsistentlybetterEFSthanTCtreatment:theestimated5-yearEFSwas66.1%vs.29.8%(P=0.002).Moreover,theestimated5-yearOSwasalsoinfavorofTAC:88.4%vs.51.6%(P<0.001).Multivariableanalysisdemonstratedthatthetreatmentregimenwasanindependentprognosticfactor,andpatientstreatedwithTAChadasuperiorEFS[hazardratio(HR),0.48;95%confidenceinterval(95%CI),0.26–0.90;P=0.021]andOS(HR,0.20;95%CI,0.08–0.60;P=0.003).Conclusions:Theupdatedlong-termfollow-updatademonstratedasustainedbenefitinEFSandOSfromanthracycline-containingTACtreatment,indicatingthatanthracyclineisanessentialandeffectivedruginthisclinicaltrial.